|
SELECT PUBLICATIONS
Arkenau H et al. Infusional 5-fluorouracil/
folinic acid plus oxaliplatin (FUFOX) versus
capecitabine plus oxaliplatin (CAPOX) as first
line treatment of metastatic colorectal cancer
(MCRC): Results of the safety and efficacy
analysis. Proc ASCO 2005;Abstract 3507.
Borner MM et al. A randomized phase II trial
of capecitabine and two different schedules of
irinotecan in first-line treatment of metastatic
colorectal cancer: Efficacy, quality-of-life and
toxicity. Ann Oncol 2005;16(2):282-8. Abstract
Buyse M et al. Progression-Free Survival (PFS)
as a surrogate for overall survival (OS) in
patients with advanced colorectal cancer: An
analysis of 3159 patients randomized in 11
trials. Proc ASCO 2005;Abstract 3513.
Chang DZ, Abbruzzese JL. Capecitabine plus
oxaliplatin vs infusional 5-fluorouracil plus
oxaliplatin in the treatment of colorectal
cancer. Pro: The CapeOx regimen is preferred
over FOLFOX. Clin Adv Hematol Oncol 2005;3(5):400-4. No abstract available
Chawla A et al. Quality of life (QoL) impact
of bevacizumab (BV) when combined with
irinotecan + 5-FU/leucovorin (IFL) and 5-FU/
leucovorin (FL) for metastatic colorectal cancer
(mCRC). Proc ASCO 2005;Abstract 3564.
Chong G, Cunningham D. Gastrointestinal
cancer: Recent developments in medical
oncology. Eur J Surg Oncol 2005;31(5):453-60.
Abstract
Collins TS, Hurwitz HI. Targeting vascular
endothelial growth factor and angiogenesis for
the treatment of colorectal cancer. Semin Oncol 2005;32(1):61-8. Abstract
Colucci G et al. Phase III randomized trial of
FOLFIRI versus FOLFOX4 in the treatment
of advanced colorectal cancer: A multicenter
study of the Gruppo Oncologico Dell’Italia
Meridionale. J Clin Oncol 2005;23(22):4866-75.
Abstract
Cunningham D et al. Cetuximab monotherapy
and cetuximab plus irinotecan in irinotecanrefractory
metastatic colorectal cancer. N Engl J
Med 2004;351(4):337-45. Abstract
Delaunoit T et al. Chemotherapy permits resection
of metastatic colorectal cancer: experience
from Intergroup N9741. Ann Oncol 2005;16(3):425-9. Abstract
Ducreux M et al. Phase III, randomized, openlabel
study of capecitabine (X) plus oxaliplatin
(XELOX) vs infusional 5-FU/LV plus oxaliplatin
(FOLFOX-6) first-line treatment in patients
(pts) with metastatic colorectal cancer (MCRC):
Findings from an interim safety analysis. Proc
ASCO 2005;Abstract 3596.
Ellis LM et al. Surgical resection after
downsizing of colorectal liver metastasis
in the era of bevacizumab. J Clin Oncol 2005;23(22):4853-5. No abstract available
Emmanouilides C et al. Anti-VEGF antibody
bevacizumab (Avastin) with 5FU/LV as third
line treatment for colorectal cancer. Tech
Coloproctol 2004;8(Suppl 1):50-2. Abstract
Feliu J et al. Capecitabine as first-line treatment
for patients older than 70 years with metastatic
colorectal cancer: An oncopaz cooperative group
study. J Clin Oncol 2005;23(13):3104-11. Abstract
Fernando N et al. A phase II study of oxaliplatin,
capecitabine and bevacizumab in the treatment
of metastatic colorectal cancer. Proc ASCO 2005;Abstract 3556.
Ferrara N et al. Bevacizumab (Avastin), a
humanized anti-VEGF monoclonal antibody
for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328-35. Abstract
Fuchs CS et al. Phase III comparison of two
irinotecan dosing regimens in second-line
therapy of metastatic colorectal cancer. J Clin
Oncol 2003;21(5):807-14. Abstract
Giantonio BJ et al. High-dose bevacizumab
improves survival when combined with
FOLFOX4 in previously treated advanced
colorectal cancer: Results from the Eastern
Cooperative Oncology Group (ECOG) study
E3200. Proc ASCO 2005;Abstract 2.
Goldberg RM et al. A randomized controlled
trial of fluorouracil plus leucovorin, irinotecan,
and oxaliplatin combinations in patients with
previously untreated metastatic colorectal
cancer. J Clin Oncol 2004;22(1):23-30. Abstract
Grothey A, Goldberg RM. A review of oxaliplatin
and its clinical use in colorectal cancer. Expert
Opin Pharmacother 2004;5(10):2159-70. Abstract
Grothey A. Oxaliplatin-safety profile:
Neurotoxicity. Semin Oncol 2003;30(4 Suppl
15):5-13. Abstract
Hecht JR et al. A randomized, double-blind,
placebo-controlled, phase III study in patients
(Pts) with metastatic adenocarcinoma of the
colon or rectum receiving first-line chemotherapy
with oxaliplatin/5-fluorouracil/
leucovorin and PTK787/ZK 222584 or
placebo (CONFIRM-1). Proc ASCO 2005. Abstract
Ho C et al. Population-based analysis of patients
with advanced colorectal cancer: The impact
of age on treatment and outcomes. Proc ASCO 2005;Abstract 3614.
Hochster HS. Capecitabine plus oxaliplatin vs
infusional 5-fluorouracil plus oxaliplatin in the
treatment of colorectal cancer. Con: Pumpin’ FU
(or, avoiding that oral fixation). Clin Adv Hematol
Oncol 2005;3(5):405-6. No abstract available
Hochster HS et al. Safety and efficacy of bevacizumab
(Bev) when added to oxaliplatin/fluoropyrimidine
(O/F) regimens as first-line treatment
of metastatic colorectal cancer (mCRC):
TREE 1 & 2 Studies. Proc ASCO 2005;Abstract 3515.
Holden SN et al. Benefit from bevacizumab (BV)
is independent of pretreatment plasma vascular
endothelial growth factor-A (pl-VEGF) in
patients (pts) with metastatic colorectal cancer
(mCRC). Proc ASCO 2005;Abstract 3555.
Hudis CA. Clinical implications of antiangiogenic
therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract
Hurwitz HI et al. Bevacizumab in combination
with fluorouracil and leucovorin: An active
regimen for first-line metastatic colorectal
cancer. J Clin Oncol 2005;23(15):3502-8. Abstract
Hurwitz H et al. Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Ignoffo RJ. Overview of bevacizumab: A new
cancer therapeutic strategy targeting vascular
endothelial growth factor. Am J Health Syst
Pharm 2004;61(21 Suppl 5):21-6. Abstract
Kabbinavar FF et al. Addition of bevacizumab
to bolus fluorouracil and leucovorin in firstline
metastatic colorectal cancer: Results
of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-705. Abstract
Kabbinavar FF et al. Combined analysis of
efficacy: The addition of bevacizumab to
fluorouracil/leucovorin improves survival for
patients with metastatic colorectal cancer. J Clin
Oncol 2005;23(16):3706-12. Abstract
Kabbinavar F et al. Phase II, randomized trial
comparing bevacizumab plus fluorouracil (FU)/
leucovorin (LV) with FU/LV alone in patients
with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract
Kelly H, Goldberg RM. Systemic therapy for
metastatic colorectal cancer: Current options,
current evidence. J Clin Oncol 2005;23(20):4553-
60. Abstract
Kemeny N et al. Randomized multicenter phase
II trial of bolus plus infusional fluorouracil/
leucovorin compared with fluorouracil/leucovorin
plus oxaliplatin as third-line treatment of
patients with advanced colorectal cancer. J Clin
Oncol 2004;22(23):4753-61. Abstract
Kemeny MM et al. Combined-modality treatment
for resectable metastatic colorectal carcinoma
to the liver: Surgical resection of hepatic
metastases in combination with continuous
infusion of chemotherapy — an intergroup
study. J Clin Oncol 2002;20(6):1499-505. Abstract
Kerr DJ et al. Intrahepatic arterial versus
intravenous fluorouracil and folinic acid for
colorectal cancer liver metastases: A multicentre
randomised trial. Lancet 2003;361(9355):368-73.
Abstract
Khamly K et al. Beyond 5-fluorouracil: New
horizons in systemic therapy for advanced
colorectal cancer. Expert Opin Investig Drugs 2005;14(6):607-28. Abstract
Kohne CH et al. Phase III study of weekly
high-dose infusional fluorouracil plus folinic
acid with or without irinotecan in patients
with metastatic colorectal cancer: European
Organisation for Research and Treatment of
Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23(22):4856-65. Abstract
Kozloff M et al. Safety of bevacizumab (BV,
Avastin™) among patients (pts) receiving
first-line chemotherapy (CT) for metastatic
colorectal cancer (mCRC) — Preliminary results
from a larger registry in the US. Proc ASCO 2005;Abstract 3566.
Lenz HJ et al. Consistent response to treatment
with cetuximab monotherapy in patients
with metastatic colorectal cancer. Proc ASCO 2005;Abstract 3536.
Mancuso A, Sternberg CN. Colorectal cancer and
antiangiogenic therapy: What can be expected
in clinical practice? Crit Rev Oncol Hematol 2005;55(1):67-81. Abstract
Mass RD et al. Clinical benefit from bevacizumab
(BV) in responding (R) and nonresponding
(NR) patients (pts) with metastatic
colorectal cancer (mCRC). Proc ASCO 2005;Abstract 3514.
McKendrick J, Coutsouvelis J. Capecitabine:
Effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005;6(7):1231-9.
Abstract
Meyerhardt JA, Mayer RJ. Systemic therapy for
colorectal cancer. N Engl J Med 2005;352(5):476-
87. No abstract available
Midgley R, Kerr D. Bevacizumab — Current
status and future directions. Ann Oncol 2005;16(7):999-1004. Abstract
Motl S. Bevacizumab in combination chemotherapy
for colorectal and other cancers. Am J
Health Syst Pharm 2005;62(10):1021-32. Abstract
Nygren P et al. Targeted drugs in metastatic
colorectal cancer with special emphasis on
guidelines for the use of bevacizumab and cetuximab:
An Acta Oncologica expert report. Acta
Oncol 2005;44(3):203-17. Abstract
Pitot HC et al. N9841: A randomized phase III
equivalence trial of irinotecan (CPT-11) versus
oxaliplatin/5-fluorouracil (5FU)/leucovorin
(FOLFOX4) in patients (pts) with advanced
colorectal cancer (CRC) previously treated with
5FU. Proc ASCO 2005;Abstract 3506.
Rhee J, Hoff PM. Angiogenesis inhibitors in the
treatment of cancer. Expert Opin Pharmacother 2005;6(10):1701-11. Abstract
Rothenberg ML et al. Superiority of oxaliplatin
and fluorouracil-leucovorin compared with
either therapy alone in patients with progressive
colorectal cancer after irinotecan and
fluorouracil-leucovorin: Interim results of a
phase III trial. J Clin Oncol 2003;21(11):2059-69.
Abstract
Rowland KM et al. Results of 3rd line therapy
on N9841: A randomized phase III trial of
oxaliplatin/5-fluorouracil (5FU)/leucovorin
(FOLFOX4) versus irinotecan (CPT-11) in
patients (pts) with advanced colorectal cancer
(CRC) previously treated with prior 5FU chemotherapy. Proc ASCO 2005;Abstract 3519.
Salesi N et al. Clinical experience with bevacizumab
in colorectal cancer. Anticancer Res 2005;25(5):3619-23. Abstract
Saltz LB et al. Randomized phase II trial of
cetuximab/bevacizumab/irinotecan (CBI) versus
cetuximab/bevacizumab (CB) in irinotecanrefractory
colorectal cancer. Proc ASCO 2005;Abstract 3508.
Sastre J et al. Preliminary results of a randomized
phase III trial of the TTD Group
comparing capecitabine and oxaliplatin
(CapeOx) vs oxaliplatin and 5-Fluorouracil in
continuous infusion (5-FU CI) as first line treatment
in advanced or metastatic colorectal cancer
(CRC). Proc ASCO 2005;Abstract 3524.
Scappaticci FA et al. Surgical wound healing
complications in metastatic colorectal cancer
patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-80. Abstract
Schalhorn A et al. Phase III trial of irinotecan
plus oxalipatin (IROX) versus irinotecan plus
5-FU/folinic acid (FOLFIRI) as first-line treatment
of metastatic colorectal cancer (CRC): The
FIRE-Trial. Proc ASCO 2005;Abstract 3516.
Scheithauer W et al. Randomized multicenter
phase II trial of two different schedules of
capecitabine plus oxaliplatin as first-line treatment
in advanced colorectal cancer. J Clin Oncol 2003;21(7):1307-12. Abstract
Scheithauer W et al. Randomized multicenter
phase II trial of oxaliplatin plus irinotecan
versus raltitrexed as first-line treatment
in advanced colorectal cancer. J Clin Oncol 2002;20(1):165-72. Abstract
Tournigand C et al. FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR
study. J Clin Oncol 2004;22(2):229-37. Abstract
Van Cutsem E et al. Oral capecitabine: Bridging
the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract
Van Cutsem E et al. Oral capecitabine vs intravenous
5-fluorouracil and leucovorin: Integrated
efficacy data and novel analyses from two
large, randomised, phase III trials. Br J Cancer 2004;90(6):1190-7. Abstract
Venook A. Critical evaluation of current treatments
in metastatic colorectal cancer. Oncologist 2005;10(4):250-61. Abstract
Verheul HM, Pinedo HM. Inhibition of angiogenesis
in cancer patients. Expert Opin Emerg
Drugs 2005;10(2):403-12. Abstract
Whisenant J, Bergsland E. Anti-angiogenic strategies
in gastrointestinal malignancies. Curr Treat
Options Oncol 2005;6(5):411-21. Abstract
Wiedmann MW, Caca K. Molecularly targeted
therapy for gastrointestinal cancer. Curr Cancer
Drug Targets 2005;5(3):171-93. Abstract
Willett CG et al. Direct evidence that the VEGFspecific
antibody bevacizumab has antivascular
effects in human rectal cancer. Nature Med 2004;10(2):145-7. Abstract
|
